Unintended Interruption of Caplacizumab Therapy Can Compromise Outcomes in Immune-Mediated Thrombotic Thrombocytopenic Purpura: Lessons from Two Clinical Cases.

Rituxan (rituximab) - Roche

Cablivi (caplacizumab-yhdp) - Sanofi

http://www.ncbi.nlm.nih.gov/pubmed/42739607

Alexandra Brinkhoff; Fahri Kiziler; Fedai Özcan; Lucas Kühne; Paul Brinkkoetter; Paul Knöbl

Sep 16, 2026